These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies. Coecke S; Goldberg AM; Allen S; Buzanska L; Calamandrei G; Crofton K; Hareng L; Hartung T; Knaut H; Honegger P; Jacobs M; Lein P; Li A; Mundy W; Owen D; Schneider S; Silbergeld E; Reum T; Trnovec T; Monnet-Tschudi F; Bal-Price A Environ Health Perspect; 2007 Jun; 115(6):924-31. PubMed ID: 17589601 [TBL] [Abstract][Full Text] [Related]
6. Towards a regulatory use of alternative developmental neurotoxicity testing (DNT). Terron A; Bennekou SH Toxicol Appl Pharmacol; 2018 Sep; 354():19-23. PubMed ID: 29454059 [TBL] [Abstract][Full Text] [Related]
7. Developmental neurotoxicity - challenges in the 21st century and in vitro opportunities. Smirnova L; Hogberg HT; Leist M; Hartung T ALTEX; 2014; 31(2):129-56. PubMed ID: 24687333 [TBL] [Abstract][Full Text] [Related]
8. International Regulatory and Scientific Effort for Improved Developmental Neurotoxicity Testing. Sachana M; Bal-Price A; Crofton KM; Bennekou SH; Shafer TJ; Behl M; Terron A Toxicol Sci; 2019 Jan; 167(1):45-57. PubMed ID: 30476307 [TBL] [Abstract][Full Text] [Related]
9. Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes. Fritsche E; Grandjean P; Crofton KM; Aschner M; Goldberg A; Heinonen T; Hessel EVS; Hogberg HT; Bennekou SH; Lein PJ; Leist M; Mundy WR; Paparella M; Piersma AH; Sachana M; Schmuck G; Solecki R; Terron A; Monnet-Tschudi F; Wilks MF; Witters H; Zurich MG; Bal-Price A Toxicol Appl Pharmacol; 2018 Sep; 354():3-6. PubMed ID: 29447839 [TBL] [Abstract][Full Text] [Related]
10. Reference compounds for alternative test methods to indicate developmental neurotoxicity (DNT) potential of chemicals: example lists and criteria for their selection and use. Aschner M; Ceccatelli S; Daneshian M; Fritsche E; Hasiwa N; Hartung T; Hogberg HT; Leist M; Li A; Mundi WR; Padilla S; Piersma AH; Bal-Price A; Seiler A; Westerink RH; Zimmer B; Lein PJ ALTEX; 2017; 34(1):49-74. PubMed ID: 27452664 [TBL] [Abstract][Full Text] [Related]
11. Developmental neurotoxicity test guidelines: problems and perspectives. Tohyama C J Toxicol Sci; 2016; 41(Spec):SP69-SP79. PubMed ID: 28250285 [TBL] [Abstract][Full Text] [Related]
12. Screening for Developmental Neurotoxicity at the National Toxicology Program: The Future Is Here. Behl M; Ryan K; Hsieh JH; Parham F; Shapiro AJ; Collins BJ; Sipes NS; Birnbaum LS; Bucher JR; Foster PMD; Walker NJ; Paules RS; Tice RR Toxicol Sci; 2019 Jan; 167(1):6-14. PubMed ID: 30496580 [TBL] [Abstract][Full Text] [Related]
13. In vitro and other alternative approaches to developmental neurotoxicity testing (DNT). Lein P; Silbergeld E; Locke P; Goldberg AM Environ Toxicol Pharmacol; 2005 May; 19(3):735-44. PubMed ID: 21783550 [TBL] [Abstract][Full Text] [Related]
14. Strategies to improve the regulatory assessment of developmental neurotoxicity (DNT) using in vitro methods. Bal-Price A; Pistollato F; Sachana M; Bopp SK; Munn S; Worth A Toxicol Appl Pharmacol; 2018 Sep; 354():7-18. PubMed ID: 29476865 [TBL] [Abstract][Full Text] [Related]
15. OECD/EFSA workshop on developmental neurotoxicity (DNT): The use of non-animal test methods for regulatory purposes. Fritsche E; Crofton KM; Hernandez AF; Hougaard Bennekou S; Leist M; Bal-Price A; Reaves E; Wilks MF; Terron A; Solecki R; Sachana M; Gourmelon A ALTEX; 2017; 34(2):311-315. PubMed ID: 28407175 [No Abstract] [Full Text] [Related]
16. Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity. Bal-Price A; Hogberg HT; Crofton KM; Daneshian M; FitzGerald RE; Fritsche E; Heinonen T; Hougaard Bennekou S; Klima S; Piersma AH; Sachana M; Shafer TJ; Terron A; Monnet-Tschudi F; Viviani B; Waldmann T; Westerink RHS; Wilks MF; Witters H; Zurich MG; Leist M ALTEX; 2018; 35(3):306-352. PubMed ID: 29485663 [TBL] [Abstract][Full Text] [Related]
17. Strategies and tools for preventing neurotoxicity: to test, to predict and how to do it. Llorens J; Li AA; Ceccatelli S; Suñol C Neurotoxicology; 2012 Aug; 33(4):796-804. PubMed ID: 22342764 [TBL] [Abstract][Full Text] [Related]
18. An industry perspective: A streamlined screening strategy using alternative models for chemical assessment of developmental neurotoxicity. Li J; Settivari R; LeBaron MJ; Marty MS Neurotoxicology; 2019 Jul; 73():17-30. PubMed ID: 30786249 [TBL] [Abstract][Full Text] [Related]
19. A perspective on In vitro developmental neurotoxicity test assay results: An expert panel review. Juberg DR; Fox DA; Forcelli PA; Kacew S; Lipscomb JC; Saghir SA; Sherwin CM; Koenig CM; Hays SM; Kirman CR Regul Toxicol Pharmacol; 2023 Sep; 143():105444. PubMed ID: 37442267 [TBL] [Abstract][Full Text] [Related]
20. Current Availability of Stem Cell-Based In Vitro Methods for Developmental Neurotoxicity (DNT) Testing. Fritsche E; Barenys M; Klose J; Masjosthusmann S; Nimtz L; Schmuck M; Wuttke S; Tigges J Toxicol Sci; 2018 Sep; 165(1):21-30. PubMed ID: 29982830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]